Synonyms: TF-011-MMAE, HuMax-TF-ADC
Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumours mainly in cervical cancer.
CAS No. 1418731-10-8
| Description |
Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumours mainly in cervical cancer.
|
References |
|
|---|
| CAS No. | 1418731-10-8 |
|---|---|
| DAR | 4.2 |
| ADC antibody | Tisotumab |
| ADC cytotoxin | MMAE |
| Formulation | 1xPBS |
| Storage | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.